At present, patients with acute myocardial infarction generally take antiplatelet drugs for a long time, and some antiplatelet drugs such as glycoprotein (GP) IIb/IIIa receptor inhibitors may weaken the binding of CsA@PPTK with the injured endothelial cell in vivo. The gene discussed is ITGA2B; the disease is myocardial infarction.